Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-12-03
1998-12-08
Schenkman, Leonard
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514256, 514812, A61K 31505
Patent
active
058469745
ABSTRACT:
This invention provides a method for treating a condition resulting from the cessation or withdrawal of tobacco or nicotine, opioids, ethanol or combinations thereof comprising administering an effective amount of 4-chloro-5-(imidazoline-2-y(amino)-6-methoxy-2-methylpyrimidine.
REFERENCES:
patent: 4201211 (1980-05-01), Chandrasekaran et al.
patent: 4255439 (1981-03-01), Cooper
patent: 4292303 (1981-09-01), Keith et al.
patent: 4323570 (1982-04-01), Stenzel et al.
patent: 4382946 (1983-05-01), Sjoerdsma
patent: 4555397 (1985-11-01), Bachynsky
patent: 4575510 (1986-03-01), Sjoerdsma
patent: 4588739 (1986-05-01), Glassman
patent: 4683231 (1987-07-01), Glassman
patent: 4783456 (1988-11-01), Glassman
patent: 4788189 (1988-11-01), Glazer
patent: 4839177 (1989-06-01), Colombo et al.
patent: 4882163 (1989-11-01), Guse et al.
patent: 4952410 (1990-08-01), Armah et al.
patent: 4956391 (1990-09-01), Sapse
patent: 5051426 (1991-09-01), Parnell
patent: 5234947 (1993-08-01), Cherksey
patent: 5422123 (1995-06-01), Conte et al.
patent: 5464633 (1995-11-01), Conte et al.
patent: 5574052 (1996-11-01), Rose et al.
Planitz, V. "Crossover comparsion of moxonidine and clonidine in mild to moderate hypertension," Eur J. Clin. Pharmacol., 27, 147-152 (1984).
Regunathan et al., "Effects of moxonidine, an imidazoline antihypertensive agent, on second messenger systems in rat brian," Eur. J. Pharmacol. Molecular Pharmacol., 269(2), 273-276 (1994).
Glavin et al., "Effects of the selective I-1 imidazoline receptor agonist, moxonidine, on gastric secretion and gastric mucosal injury in rats," Brit. J. Pharmacol., 114, 751-754 (1995).
Haxhiu et al., "Effect of I-1-imidazoline receptor activation on responses of hypoglossal and phrenic nerve to chemical stimulation," Ann New York Acad. Sci., 763, 445-462 (1995).
Webster et al., "Aspects of tolerability of centrally acting antihypertensive drugs," J. Cardiovasc. Pharmacol., 27 (suppl. 3), S49-S54 (1996).
Rupp et al., "Drug withdrawal and rebound hypertension," Cardiovasc. Drugs, Therap., 10 (suppl. 1), 251-262 (1996).
Scientific Information Brochure, Selective imidazoline receptor agonist for the treatment of hypertension, Beiersdorf-Lilly and Lilly Deutshland.
J. P. Ollivier et al., I.sub.1 -Imidazoline-Receptor Agonists in the Treatment of Hypertension: An Appraisal of Clinical Experience, Journal of Cardiovascular Pharmacology, 24 (Suppl. 1), S39-S48 (1994).
U.S. application No. 08/659463, McNay, filed Jun. 6, 1996.
Paul Ernsberger et al., Moxonodine: A Second-generation Central Antihypertensive Agent, Cardiovascular Drug Reviews, vol. 11, No. 4, 411-431 (1993).
Martin C. Michel et al., From .alpha..sub.2 -Adrenoceptors to Imidazoline Receptors: Putative Progress for Cardiovascular Therapy, Journal of Cardiovascular Pharmacology, 20 (Suppl. 4 ), S24-S30 (1992).
G. Trieb, M.D., et al., Long-term evaluation of the antihypertensive efficacy and tolerability of the orally acting imidazoline I.sub.1 receptor agonist moxonidine, European Journal of Clinical Research, vol. 7, 227-240 (1995).
Selective Imidazoline Receptor Agonist, Moxonidine Physiotens, (Jun., 1996).
K. I. Pearce, Clonidine And Smoking, The Lancet, 810 (1986).
Alexander H. Glassman et al., Cigarette Craving, Smoking Withdrawal, and Clonidine, Science, vol. 226, 864-866 (1984).
Lirio S. Covey et al., A meta-analysis of double-blind placebo-controlled trials of clonidine for smoking cessation, British Journal of Addiction, 86, 991-998 (1991).
Alexander H. Glassman et al., Future Trends in the Pharmacological Treatment of Smoking Cessations, Drugs, 40(I), 1-5 (1990).
Lirio S. Covey, Ph.D. et al., New Approaches to Smoking Cessation, Drug Therapy, 55-58 (1990).
Margaret A. Willan, Effectiveness of Clonidine in Smoking Cessation, The Canadian Journal of Hospital Pharmacy, vol. 45, No. 2, 77-78 (1992).
Allan V. Prochazka, M.D. et al., Transdermal Clonidine Reduced Some Withdrawal Symptoms but Did not Increase Smoking Cessation, Arch Intern Med., vol. 152, 2065-2069 (1992).
Peter Franks, M.D. et al., Randomized, Controlled Trial of Clonidine for Smoking Cessation in a Primary Care Setting, JAMA, vol. 262, No. 21, 3011-3013 (1989).
William S. Bond, Psychiatric Indications for Clonidine: The Neuropharmacologic and Clinical Basis, J. Clin. Psychopharmacol, vol. 6, No. 2, 81-87 (1986).
Steven G. Gourlay et al., Is Clonidine an Effective Smoking Cessation Therapy?, Drugs, 50(2), 197-207 (1995).
Herbert D. Kleber, M.D., Clonidine and Naltrexone in the Outpatient Treatment of Heroin Withdrawal, Am. J. Drug Alcohol Abuse, 13 (1 & 2), 1-17 (1987).
Daniel E. Hilleman et al., Randomized, Controlled Trial of Transdermal Clonidine For Smoking Cessation, The Annals of Pharmacotherapy, vol. 27, 1025-1028 (1993).
Steven Gourlay et al., A placebo-controlled study of three clonidine doses for smoking cessation, Clinical Pharmacology & Therapeutics, vol. 55, No. 1, 64-69 (1994).
Alexander H. Glassman, M.D. et al., Heavy Smokers, Smoking Cessation, and Clonidine, JAMA, vol. 259, No. 19 (1988).
Hao Wei, M.D. et al., Effect of Clonidine on Cigarette Cessation and in the Alleviation of Withdrawal Symptoms, British Journal of Addiction, 83, 1221-1226 (1988).
Alexander H. Glassman, M.D. et al., Smoking cessation, clonidine, and vulnerability to nicotine among dependent smokers, Clinical Pharmacology & Therapeutics, vol. 54, No. 6, 670-679 (1993).
Richard Davison, M.D. et al., The effect of clonidine on the cessation of cigarette smoking, Clin. Pharmacol Ther., vol. 44, No. 3, 265-267 (1988).
Steven A. Ornish et al., Effects of Transdermal Clonidine Treatment on Withdrawal Symptoms Assciated With Smoking Cessation, Arch Intern Med., vol. 148, 2027-2031 (1988).
S. Said et al., Essais controles randomises d'aides medicamenteuses de l'arrret du tabac -Resultats et perspectives, Therapie, 49, 313-319 (1994).
Jose Luis Cervantes Escarcega et al., Efecto De La Terapia Transdermica Con Clonidina En Los Sintomas De Supresion Secundarios Al Cese Del Consumo De Tabaco, Arch Inst. Cardiol Mex, vol. 62, 435-440 (1992).
Pr. G. Lagrue, Clonidine, Depression et Arret Du tabac, Concours Med., 2260-2261 (1988).
Diane Moniz, PharmD, Clonidine and Cigarettes, Hospital Therapy, 171-172, 174 (1990).
Steven G. Gourlay et al., Antismoking products, The Medical Journal of Australia, vol. 153, 699-707 (1990).
Kallman Mary J.
Rasmussen Kurt
Boone David E.
Demeter John C.
Eli Lilly and Company
Schenkman Leonard
LandOfFree
Method for treating substance abuse withdrawal does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating substance abuse withdrawal, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating substance abuse withdrawal will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-177499